-
June 18, 2013
Novartis recently presented positive results on oncology drug Jakavi from a three-year follow up analysis of a phase ...
-
June 18, 2013
MannKind completed a phase III study on its diabetes candidate Afrezza.
-
June 14, 2013
Novartis recently presented new data on Gilenya from a phase III study, TRANSFORMS.
-
June 13, 2013
The FDA updated Incyte's sole marketed product Jakafi's label.
-
February 08, 2013
Alnylam Pharmaceuticals Inc.'s (ALNY) fourth quarter 2012 loss of $1.20 per share was narrower than the Zacks ...
-
January 24, 2013
Cubist Pharmaceuticals Inc.'s (CBST) fourth quarter 2012 earnings (excluding special items) of 48 cents per share ...
-
January 22, 2013
We expect Cubist Pharmaceuticals Inc. (CBST) to beat expectations when it releases its fourth-quarter 2012 results ...
-
January 09, 2013
Optimer Pharmaceuticals Inc. (OPTR) recently announced its preliminary sales for the fourth quarter and full year ...
-
January 08, 2013
Cubist Pharmaceuticals Inc.'s (CBST) unaudited net revenues for the fourth quarter of 2012 climbed 16% year over ...
-
January 02, 2013
Given the recent run-up in the market, here's a screen I've been using recently for my own stock picking.
First, ...
-
December 24, 2012
Cubist Pharmaceuticals Inc. (CBST) announced that it has filed for the approval of its drug Entereg (alvimopan) for ...
-
December 07, 2012
Cubist Pharmaceuticals Inc. (CBST) received some encouraging news recently when the US Food and Drug Administration ...
-
December 04, 2012
Optimer Pharmaceuticals (OPTR) recently decided to collaborate with AstraZeneca (AZN) for the commercialization of ...
-
November 07, 2012
Alnylam Pharmaceuticals Inc.'s (ALNY) third quarter 2012 net loss of 38 cents per share was wider than the year-ago ...
-
November 02, 2012
Optimer Pharma's (OPTR) third quarter 2012 net loss (excluding special items) of 56 cent per share was narrower than ...
-
October 19, 2012
Cubist Pharmaceuticals Inc.'s (CBST) third quarter 2012 adjusted earnings of 68 cents per share breezed past the ...
-
October 19, 2012
The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is ...
-
October 17, 2012
Cubist Pharmaceuticals Inc. (CBST) is all set to report its third quarter 2012 results on October 18, 2012. The ...
-
October 09, 2012
Optimer Pharmaceuticals, Inc. (OPTR) recently announced its decision to sell its stake in Optimer Biotechnology, ...
-
September 24, 2012
The Nasdaq has fallen 0.7%, the S&P 500 has fallen 0.2% and the Dow has declined 0.2% on a bad morning for the ...
